Gyowa kirin

News release

Kyowa Kirin Announces Organizational Changes in Quality Assurance and Pharmacovigilance Functions

Tokyo, Japan, November 26, 2019 – Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, "Kyowa Kirin") announces today that the company will change its Quality Assurance and Pharmacovigilance Functions effective January 1, 2020.

Outline of the organizational Changes


- 1. Quality Division and Pharmacovigilance (PV) Division will be newly established and report directly to the President & CEO.
- 2. Quality Assurance Department and Regulatory Audit Department will be established within the Quality Division.
- 3. PV Business Management Department, PV Operations Department and PV Medical Department will be established within the Pharmacovigilance Division.

Purpose of the organizational changes

- Clarify the roles and responsibilities of the Quality Assurance Function and Pharmacovigilance (PV) Function by operating as independent organizations.
- 2. Pursue the maintenance and improvement of the quality of pharmaceuticals supplied globally throughout the product life cycle by establishing and operating a quality management system based on the global quality policy.
- 3. Pursue the proper use of pharmaceuticals and the safety of patients by complying with the relevant regulations, conducting safety monitoring activities, and formulating safety measures.



Company organization chart



About Kyowa Kirin

Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on creating new value in the four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, employees from 36 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers in discovering solutions wherever there are unmet medical needs. You can learn more about the business of Kyowa Kirin at https://www.kyowakirin.com.

#